PANDAS/PANS is a clinically distinct entity and needs early and prompt immunotherapy
Capsule: The nosology of pediatric acute neuropsychiatric syndromes remains controversial, and the evidence for immunopathology and in particular autoimmunity driven by Streptococcal infection remains controversial. Is this a distinct disorder and is prompt immunotherapy indicated for treatment?
08:30-08:40
Host: Alicja Kalinowska, Poland
08:40-08:55
Yes: Ronny Wickström, Sweden
08:55-09:10
No: Ming Lim, UK
09:10-09:20
Discussion and rebuttals
09:20-10:10
Treatment of CIDP – immunoglobulins or steroids first?
Capsule: Many treatments have been advocated for CIDP, but the best accepted options are intravenous immunoglobulin and corticosteroids. Which treatment is best and should be applied first?
09:20-09:30
Host: Joab Chapman, Israel
09:30-09:45
Immunoglobulins: MarinosDalakas, USA
09:45-10:00
Steroids: Eduardo Nobile-Orazio, Italy
10:00-10:10
Discussion and rebuttals
10:10-10:25
Coffee Break
10:25-12:05
NEUROMYELITIS OPTICA SPECTRUM DISORDER
10:25-11:15
New regulatory-approved medications should be used exclusively for prevention of attacks of NMOSD over (currently used) non-regulatory approved medications
Capsule: It is likely that 3 immunomodulatory treatments, a C5 complement inhibitor, an anti-CD19 monoclonal antibody and an inhibitor of IL6 receptor, will all receive regulatory approval for treatment of NMOSD; do these drugs offer sufficient advantages that they should replace currently widely-used immunotherapies that are widely regarded as effective and may be less expensive?
10:25-10:35
Host: BrianWeinshenker, USA
10:35-10:50
Yes: Friedemann Paul, Germany
10:50-11:05
No: Andrzej Glabinki, Poland
11:05-11:15
Discussion and rebuttals
11:15-12:05
NMOSD attacks should be treated with apheresis/plasma exchange at first presentation, either with or without corticosteroids
Capsule: Recent retrospective experience suggests that concomitant or first line treatment with plasma exchange may be superior to first line treatment with corticosteroids. Is a change in the standard approach of using corticosteroids first appropriate given the current state of knowledge?
11:15-11:25
Host: Bruno Gran, UK
11:25-11:40
Yes: Ingo Kleiter, Germany
11:40-11:55
No: M Isabel Leite, UK
11:55-12:05
Discussion and rebuttals
12:05-13:15
Industry Symposium
13:15-14:15
Lunch Break
14:15-15:45
SECTION TITLE
14:15-14:55
2015 International Panel criteria for NMOSD are outdated and should be replaced with a diagnostic classification primarily based on autoantibody status rather than clinical presentation (e.g. AQP4 disease, MOG disease)
Capsule: We now know the molecular target of the autoimmune insult in the majority of patients with NMOSD, and we can use a molecular classification based on the target of the antibody in lieu of clinical criteria for diagnosis of what we currently refer to as NMOSD. Some would argue “not so fast.” Are we ready for a molecular classification of NMOSD in 2020?
14:15-14:25
Host: Jacek Losy, Poland
14:25-14:35
Yes: Angela Vincent, UK
14:35-14:45
No: Ingo Kleiter, Germany
14:45-14:55
Discussion and rebuttals
14:55-15:45
Is narcolepsy an autoimmune disorder which should be treated as such?